Tech Company Financing Transactions
T-CURX Funding Round
T-CURX, based in Würzburg, raised $20 million in investment from BioMed Ventures, Bayern Kapital and HighLight Capital.
Transaction Overview
Company Name
Announced On
12/17/2025
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate clinical development of its non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing proprietary non-viral technologies for in vivo CAR-T generation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Friedrich-Bergius-Ring 15
Würzburg, 97076
Germany
Würzburg, 97076
Germany
Phone
Website
Email Address
Overview
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ulf Grawunder
Browse more venture capital transactions:
Prev: 12/17/2025: DNA Nanobots venture capital transaction
Next: 12/17/2025: Clarity Pediatrics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs